S908
Clinical - Mixed sites & palliation
ESTRO 2026
Domínguez 1 , Marc Beltrán Gallén 2 , Ferran Guedea Edo 1 , Maria Aranzazu Eraso Urién 1 1 Radiation Oncology, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain. 2 Ophthalmology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain. 3 Palliative Care, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain Purpose/Objective: Choroidal metastases (CM) often present with rapid visual loss or ocular pain. Radiotherapy (RT) is commonly used to alleviate symptoms and preserve visual function. However, the overall prognosis of these patients is frequently poor which limits the availability of long-term follow-up and makes it difficult to accurately assess treatment effectiveness. Material/Methods: We retrospectively reviewed the outcomes of patients with CM who received RT at our centre over the last 10 years. The analysis focused on those who underwent ophthalmologic assessment, including retinography, ocular ultrasound, optic coherence tomography and visual acuity testing, at least 6 months after treatment Results:
Of 218 patients treated with PBT, 106 were eligible for the present analysis. Median age was 68 years (65.9 ± 13.5 years); 56% were female. Most frequent tumor sites were prostate (27%), breast (27%) and head and neck (13%). Approximately 80% of patients received hypofractionated regimens. Questionnaire completion rates were 97% at baseline, 77% at end of treatment, 56% at 3 months, and 35% at 6 months. Median GHS remained high and stable across follow-up, indicating preserved well-being. Head and neck patients showed a slight GHS decline at 6 months, though functional scales were mostly stable. Prostate patients maintained high functioning with minimal symptom burden. Breast patients experienced mild, temporary fluctuations in emotional and role functioning with recovery over time. Symptom burden overall remained low. Larger tumor volume and lower baseline performance status correlated with lower GHS ( ρ = –0.32 and ρ = 0.24; p < 0.05). Conclusion: Proton reRT was well tolerated and preserved HRQoL across disease sites. These findings support PBT as an effective reirradiation approach also when hypofractionated schedules have been used. Keywords: quality of life, reirradiation, proton therapy
Nineteen patients were identified. Median age was 62 years [40-82], 53% were male. The most frequent primary tumours were lung (47%) and breast (21%). Most CM were metachronous (74%) and associated with polymetastatic disease (58%). Bilateral ocular involvement occurred in 21%. The median maximum lesion diameter was 12 mm [6-20], with a median thickness of 2.5 mm [1-14]. Baseline visual acuity was severely impaired (<0.2) in 53% of patients. The most common RT regimens were 30 Gy in 10 fractions (53%) and 20 Gy in 5 fractions (37%). Treatment was well tolerated, with only grade 2 ocular toxicity reported in
Digital Poster 3956 Long-term ophthalmologic outcomes after radiotherapy for choroidal metastases: a single- centre cohort study Anna Lucas Calduch 1 , Daniel Lorenzo Parra 2 , Josep Maria Caminal Mitjana 2 , Andrea Slocker Scarpa 1 , Miquel Macià Garau 1 , Nagore García Expósito 1 , Roser Cuadros Margarit 3 , Margherita Moretti 1 , Marc Ruíz
Made with FlippingBook - Share PDF online